Clinical Trials Adults with Acute Myelogenous Leukemia: Experience of the Eastern Cooperative Oncology Group

  • J. M. Rowe
  • J. W. Andersen
  • P. A. Cassileth
  • M. M. Oken
  • J. M. Bennett
  • P. H. Wiernik
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)


Over the past 15 years, the Eastern Cooperative Oncology Group has conducted a series of studies in patients with AML, sequentially escalating the post-remission therapy. While there has not been a major improvement in the number of adult patients who can achieve a complete remission, intensifying the post remission therapy appears to have led to an improved disease-free survival rate (Fig. 1) and has formed the basis for a major intergroup study prospectively evaluating the role of three different intensive post-remission regimens. This report will focus on de novo AML and, in addition to describing three major ongoing randomized studies, will also discuss the impact that previous ECOG studies have had on the design of current studies for dose intensity in postremission therapy.


Acute Myeloid Leukemia Eastern Cooperative Oncology Group Induction Therapy Acute Myelogenous Leukemia Cytosine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Preisler H, Davis RB, Kirschner J et al. (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute myelomonocytic leukemia: A Cancer and Leukemia Group B Study. Blood 69: 1441–1446PubMedGoogle Scholar
  2. 2.
    Mayer RJ (1987) Current chemotherapeutic approaches in the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Hematol 14: 384–397Google Scholar
  3. 3.
    Cassileth PA, Harrington DP, Hines JD et al. (1988) Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6(4): 583–587PubMedGoogle Scholar
  4. 4.
    Bennett JM, Begg CB (1981) Acute myeloid leukemia by correlation of subtypes with response and survival. Cac Res 41: 4833–4837Google Scholar
  5. 5.
    Cassileth PA, Begg CB, Bennett JM et al. (1984) A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 63: 843–847PubMedGoogle Scholar
  6. 6.
    Cassileth PA, McGlave P, Harrington DP et al. (1989) Comparison of post remission therapy in AML: Maintenance versus intensive consolidation therapy versus allogeneic bbne marrow transplantation. Proc ASCO 8: 197Google Scholar
  7. 7.
    Cassileth PA, Andersen JW, Bennett JM et al. (1992) Escalating the intensity of post-remission therapy improved the outcome in acute myeloid leukemia: The ECOG experience. Leukemia (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • J. M. Rowe
    • 1
  • J. W. Andersen
    • 2
  • P. A. Cassileth
    • 3
  • M. M. Oken
    • 4
  • J. M. Bennett
    • 5
  • P. H. Wiernik
    • 6
  1. 1.Hematology UnitUniversity of Rochester Medical CenterRochesterUSA
  2. 2.Dana Farber Cancer InstituteBostonUSA
  3. 3.Sylvester Comprehensive Cancer Center, University of MiamiMiamiUSA
  4. 4.Virginia Piper Cancer InstituteMinneapolisUSA
  5. 5.University of Rochester Cancer CenterRochesterUSA
  6. 6.Albert Einstein Cancer CenterBronxUSA

Personalised recommendations